Verenigde Staten - Engels - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - prochlorperazine maleate (unii: i1t8o1jtl6) (prochlorperazine - unii:yhp6ylt61t) - prochlorperazine 5 mg - for control of severe nausea and vomiting. for the treatment of schizophrenia. prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. however, prochlorperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines). when used in the treatment of non-psychotic anxiety, prochlorperazine should not be administered at doses of more than 20 mg per day or for longer than 12 weeks, because the use of prochlorperazine at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see warnings ). the effectiveness of prochlorperazine as treatment for non-psychotic anxiety was established in 4 week clinical studies of outpatients with generalized anxiety disorder. this evidence does not predict that prochlorperazine will be useful in patients with other non-psychotic conditions in w

Verenigde Staten - Engels - NLM (National Library of Medicine)

preferred pharmaceuticals, inc - prochlorperazine maleate (unii: i1t8o1jtl6) (prochlorperazine - unii:yhp6ylt61t) - prochlorperazine 10 mg - for control of severe nausea and vomiting. for the treatment of schizophrenia. prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. however, prochlorperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines). when used in the treatment of non-psychotic anxiety, prochlorperazine should not be administered at doses of more than 20 mg per day or for longer than 12 weeks, because the use of prochlorperazine at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see warnings ). the effectiveness of prochlorperazine as treatment for non-psychotic anxiety was established in 4 week clinical studies of outpatients with generalized anxiety disorder. this evidence does not predict that prochlorperazine will be useful in patients with other non-psychotic conditions in w

Verenigd Koninkrijk - Engels - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - prochlorperazine maleate - oral tablet - 5mg

Verenigde Staten - Engels - NLM (National Library of Medicine)

qpharma inc - prochlorperazine maleate (unii: i1t8o1jtl6) (prochlorperazine - unii:yhp6ylt61t) - prochlorperazine 10 mg - for control of severe nausea and vomiting. for the treatment of schizophrenia. prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. however, prochlorperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines). when used in the treatment of non-psychotic anxiety, prochlorperazine should not be administered at doses of more than 20 mg per day or for longer than 12 weeks, because the use of prochlorperazine at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see warnings ). the effectiveness of prochlorperazine as treatment for non-psychotic anxiety was established in 4 week clinical studies of outpatients with generalized anxiety disorder. this evidence does not predict that prochlorperazine will be useful in patients with other non-psychotic conditions in w

Australië - Engels - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - prochlorperazine maleate, quantity: 5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; wheat starch; calcium hydrogen phosphate dihydrate; sodium lauryl sulfate - nausea and vomiting due to various causes including migraine; vertigo due to meniere's syndrome, labyrinthitis and other causes.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - prochlorperazine maleate -

Verenigd Koninkrijk - Engels - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - prochlorperazine maleate - oral tablet - 5mg

Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - prochlorperazine maleate 5mg - tablet - 5 mg - active: prochlorperazine maleate 5mg excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate maize starch - prochlorperazine maleate is used in vertigo due to meniere's syndrome, labyrinthitis and other causes, and for nausea and vomiting from whatever cause. it may also be used for migraine, schizophrenia (particularly in the chronic stage), acute mania and as an adjunct to the short term management of anxiety.

Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

ipca pharma (nz) pty limited - prochlorperazine maleate 5mg - tablet - 5 mg - active: prochlorperazine maleate 5mg excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate maize starch - prochlorperazine maleate is used in vertigo due to meniere's syndrome, labyrinthitis and other causes, and for nausea and vomiting from whatever cause. it may also be used for migraine, schizophrenia (particularly in the chronic stage), acute mania and as an adjunct to the short term management of anxiety.

Verenigd Koninkrijk - Engels - MHRA (Medicines & Healthcare Products Regulatory Agency)

genesis pharmaceuticals ltd - prochlorperazine maleate - oral tablet - 5mg